2026 年 10 月 23–27 日 · Madrid · 共 4873 条
24 人 · 29 条
当前热度 1·可比范围峰值 1（10月26日 21:00）·近 24 小时可比范围变化 –·当前参与者 1
Tarlatamab是靶向DLL3×CD3的双特异性T细胞衔接器（BiTE），DLL3在SCLC细胞表面高表达而正常细胞极少表达，使其成为较理想的治疗靶点[9]。这一资产在经治SCLC中的证据链已经站住：I期研究（107例）中细胞因子释放综合征是最常见治疗相关不良事件（52%），其中3级仅1例[7]；II期研究中10mg组客观缓解率为40%（97.5% CI 29–52）[6]；2025年发表的III期研究（509例）显示二线tarlatamab对比化疗显著延长总生存[8]。该药以IMDELLTRA之名已于2024年获批上市[10]。
本次ESMO 2026总统研讨会I上，Jacob Sands报告了DeLLphi-305 III期主要分析[4]，并同日发表于NEJM：ES-SCLC患者在度伐利尤单抗+铂类+依托泊苷一线诱导后，随机接受tarlatamab+度伐利尤单抗或度伐利尤单抗单药维持。预设中期分析显示中位OS为21.1 vs 12.7个月（HR 0.42），绝对获益8.4个月；PFS为7.4 vs 1.9个月；ORR为26.4% vs 4.1%；CRS约50%且多为1–2级，不良事件增加但符合预期、可行门诊治疗。现场多位专家称之为practice changing、新标准治疗，报告获起立鼓掌；讨论环节聚焦维持策略的合理性、疗效生物标志物、可及性与公平实施，以及BiTE监测的落地难题。同场3821P还报告了DeLLphi-303 Ib期tarlatamab+抗PD-L1一线维持延长随访的持续生存[1]。
主站新闻从两条独立线索补充了图景。其一，Cancer Cell研究（Nomura等）显示肺神经内分泌癌通过上调TPH1增加血清素（5-HT），经HTR7通路诱导免疫抑制性肿瘤相关巨噬细胞、削弱CD8+ T细胞功能，从而驱动tarlatamab耐药并介导ICB耐药，且提示HTR7是潜在可成药脆弱点[N1][N3]。其二，FierceBiotech报道勃林格殷格海姆在会上展示晚期DLL3双抗管线数据，意在挑战安进Imdelltra的地位[N2]。这两条与现场读数互相印证：疗效确立的同时，耐药机制与竞争格局成为下一阶段的焦点。
相对已有认识，这次读数把tarlatamab从经治/二线推入一线维持，现场称OS几乎翻倍、中位OS接近两年，DLL3类药物正在改变SCLC的预后。局限也须交代：结果来自预设中期分析；现场帖中12个月OS率数字不完整，完整值待确认；维持与二线的最优排序、前线数据及疗效预测生物标志物仍不明，广覆盖、公平可及与BiTE门诊监测体系是现实门槛。
Presented at #ESMO26: In a prespecified interim analysis of a phase 3 trial involving patients with extensive-stage SCLC, the median overall survival was 21.1 months with tarlatamab–durvalumab maintenance therapy and 12.7 months with durvalumab alone. Full DeLLphi-305 trial results: https://nej.md/4iveIgW @myESMO
🚨🔥@OncoAlert Hot off the press. Just published @NEJM in conjunction with presentation @myESMO #ESMO26 the long-awaited #PracticeChanging results of: ⭐️#DeLLphi305 phase 3 trial of: ❇️1st line maintenance #Tarlatamab + #Durvalumab) vs #Durvalumab alone in patients with #ExtensiveStage #SmallCell #LungCancer after initial induction Tx with #Chemo + Durvalumab. Study showed: ‼️#Impressive statistically significant & clinically meaningful ⬆️#OverallSurvival Benefit. ✅#mOS: 21.1 vs 12.7 months (HR 0.42) ✅12-month OS: 79.4% vs 53.3% ✅#mPFS: 7.4 vs 1.9 months (HR 0.34) ⚠️ Grade ≥3 #AEs: 46.8% vs 40.6% * In Tarlatamab arm: #CRS: 49.6% (Grade ≥3: 0.4%) #ICANS: 1.1% (Grade ≥3: 0%) 👇🏻 https://www.nejm.org/doi/full/10.1056/NEJMoa2609482?query=featured_home
Presented at #ESMO26: In a prespecified interim analysis of a phase 3 trial involving patients with extensive-stage SCLC, the median overall survival was 21.1 months with tarlatamab–durvalumab maintenance therapy and 12.7 months with durvalumab alone. Full DeLLphi-305 trial results: https://nej.md/4iveIgW @myESMO
🆙#ESMO26 Presidential Symposium I: #LCSM 🔥DeLLphi-305: Tarlatamab Plus Durvalumab (Durva) vs Durva as 1L Maintenance (1LM) Therapy Following Durva, Platinum, and Etoposide in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Primary Analysis of the Phase 3 Trial 🎙️ @sands_jacob 🔢LBA3 🎯Met Primary Endpoint: Significantly Improved OS 🎯mOS 21.1 vs 12.7m, HR 0.42 🎯mPFS 7.4 vs 1.9m, HR 0.34 🎯ORR 26.4% vs 4.1% 🎯CRS 49.6% (Mostly Low Grade), No Fatal Events ☑️NCT06211036 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/346 @OncoAlert @Larvol @myESMO @IASLC
@myESMO #Tarlatamab #sclc #ESMO26 @StephenVLiu @BalazsHalmosMD @OncoAlert
暂无中文译文，显示英文原文。
Let’s take a look at #DeLLphi-305: the trial yields poor results in the "Americas," so you bring in a large number of Asian patients (±40%) #sclc #ESMO26 Opinions??? @StephenVLiu @drshieldsmd @Tony_Calles @LuisPaz_Ares @lungoncdoc @Annechiangmd @LealTiciana @latina @MartinReck2
暂无中文译文，显示英文原文。
Outstanding discussion by @StephenVLiu on the practice-changing DeLLphi-305 trial @sands_jacob . A new chapter in the treatment of ES-SCLC! #ESMO26. One year ago, we anticipated that we might finally be bending gravity. Today, that vision is becoming a reality!!!!!!👏👏👏👏👏
@pistoto2017 Very relevant question! Platinum rechallenge or lurbinectedin may be options. But optimal 2L sequencing after tarlatamab maintenance remains an important unanswered question!
暂无中文译文，显示英文原文。